Literature DB >> 21903983

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Ronald D Perrone1, Kaleab Z Abebe, Robert W Schrier, Arlene B Chapman, Vicente E Torres, James Bost, Diana Kaya, Dana C Miskulin, Theodore I Steinman, William Braun, Franz T Winklhofer, Marie C Hogan, Frederic Rahbari-Oskoui, Cass Kelleher, Amirali Masoumi, James Glockner, Neil J Halin, Diego Martin, Erick Remer, Nayana Patel, Ivan Pedrosa, Louis H Wetzel, Paul A Thompson, J Philip Miller, K Ty Bae, Catherine M Meyers.   

Abstract

BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) is associated with a substantial cardiovascular disease burden including early onset hypertension, intracranial aneurysms, and left ventricular hypertrophy (LVH). A 41% prevalence of LVH has been reported in ADPKD, using echocardiographic assessment of LV mass (LVM). The HALT PKD study was designed to assess the effect of intensive angiotensin blockade on progression of total kidney volume and LVM. Measurements of LVM were performed using cardiac magnetic resonance (MR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five hundred forty-three hypertensive patients with GFR >60 ml/min per 1.73 m(2) underwent MR assessment of LVM at baseline. LVM was adjusted for body surface area and expressed as LVM index (LVMI; g/m(2)).
RESULTS: Baseline BP was 125.1 ± 14.5/79.3 ± 11.6 mmHg. Average duration of hypertension was 5.79 years. Prior use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was present in 59.5% of patients. The prevalence of LVH assessed using nonindexed LVM (g) was 3.9% (n = 21, eight men and 13 women) and 0.93% (n = 5, one man and four women) using LVMI (g/m(2)). In exploratory analyses, the prevalence of LVH using LVM indexed to H(2.7), and the allometric index ppLVmass(HW), ranged from 0.74% to 2.23% (n = 4 to 12). Multivariate regression showed significant direct associations of LVMI with systolic BP, serum creatinine, and albuminuria; significant inverse associations with LVMI were found with age and female gender.
CONCLUSIONS: The prevalence of LVH in hypertensive ADPKD patients <50 years of age with short duration of hypertension, and prior use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is low. Early BP intervention in ADPKD may have decreased LVH and may potentially decrease cardiovascular mortality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903983      PMCID: PMC3186455          DOI: 10.2215/CJN.04610511

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  19 in total

1.  Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences.

Authors:  Khaled Alfakih; Sven Plein; Holger Thiele; Tim Jones; John P Ridgway; Mohan U Sivananthan
Journal:  J Magn Reson Imaging       Date:  2003-03       Impact factor: 4.813

2.  Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kimberly K McFann; Ann M Johnson
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

3.  Left ventricular hypertrophy in autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; A M Johnson; S Rainguet; K Hossack; P Gabow; R W Schrier
Journal:  J Am Soc Nephrol       Date:  1997-08       Impact factor: 10.121

4.  Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging.

Authors:  C H Lorenz; E S Walker; V L Morgan; S S Klein; T P Graham
Journal:  J Cardiovasc Magn Reson       Date:  1999       Impact factor: 5.364

5.  Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort.

Authors:  Carol J Salton; Michael L Chuang; Christopher J O'Donnell; Michelle J Kupka; Martin G Larson; Kraig V Kissinger; Robert R Edelman; Daniel Levy; Warren J Manning
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

6.  Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group.

Authors:  N Hateboer; M A v Dijk; N Bogdanova; E Coto; A K Saggar-Malik; J L San Millan; R Torra; M Breuning; D Ravine
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

Review 7.  Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

8.  Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease.

Authors:  D D Ivy; E M Shaffer; A M Johnson; W J Kimberling; A Dobin; P A Gabow
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

Review 9.  Causes of death in autosomal dominant polycystic kidney disease.

Authors:  G M Fick; A M Johnson; W S Hammond; P A Gabow
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

10.  Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification.

Authors:  Lyndia C Brumback; Richard Kronmal; Susan R Heckbert; Hanyu Ni; W Gregory Hundley; João A Lima; David A Bluemke
Journal:  Int J Cardiovasc Imaging       Date:  2010-01-27       Impact factor: 2.357

View more
  20 in total

1.  Liver involvement in early autosomal-dominant polycystic kidney disease.

Authors:  Marie C Hogan; Kaleab Abebe; Vicente E Torres; Arlene B Chapman; Kyongtae T Bae; Cheng Tao; Hongliang Sun; Ronald D Perrone; Theodore I Steinman; William Braun; Franz T Winklhofer; Dana C Miskulin; Frederic Rahbari-Oskoui; Godela Brosnahan; Amirali Masoumi; Irina O Karpov; Susan Spillane; Michael Flessner; Charity G Moore; Robert W Schrier
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-09       Impact factor: 11.382

Review 2.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

3.  Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Authors:  Ronald D Perrone; Kaleab Z Abebe; Robert W Schrier; Arlene B Chapman; Vicente E Torres; James Bost; Diana Kaya; Dana C Miskulin; Theodore I Steinman; William Braun; Franz T Winklhofer; Marie C Hogan; Frederic Rahbari-Oskoui; Cass Kelleher; Amirali Masoumi; James Glockner; Neil J Halin; Diego Martin; Erick Remer; Nayana Patel; Ivan Pedrosa; Louis H Wetzel; Paul A Thompson; J Philip Miller; K Ty Bae; Catherine M Meyers
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

Review 4.  Influence of chronic kidney disease on cardiac structure and function.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

5.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

6.  Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Antonio Concistrè; Luigi Petramala; Gianmarco Scoccia; Susanna Sciomer; Valeria Bisogni; Vincenza Saracino; Gino Iannucci; Silvia Lai; Daniela Mastroluca; Gianluca Iacobellis; Claudio Letizia
Journal:  Cardiorenal Med       Date:  2018-05-03       Impact factor: 2.041

7.  Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Authors:  Melissa A Cadnapaphornchai; Diana M George; Kim McFann; Wei Wang; Berenice Gitomer; John D Strain; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

8.  Bioactive lipid mediators in polycystic kidney disease.

Authors:  Jelena Klawitter; Jost Klawitter; Kim McFann; Alexander T Pennington; Kaleab Z Abebe; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Berenice Gitomer; Uwe Christians; Robert W Schrier
Journal:  J Lipid Res       Date:  2013-12-16       Impact factor: 5.922

9.  Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress.

Authors:  Esther Giehl; Fernanda O Lemos; Yan Huang; Frank J Giordano; Ivana Y Kuo; Barbara E Ehrlich
Journal:  Pflugers Arch       Date:  2017-07-31       Impact factor: 3.657

10.  Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors:  Asmin Andries; Kristien Daenen; François Jouret; Bert Bammens; Djalila Mekahli; Ann Van Schepdael
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.